Conference Coverage

Inadequate pain relief in OA, high opioid use before TKA


 

FROM OARSI 2022

Sharp rise in opioid use 2 years before TKA

Lower rates of opioid use before TKA were seen in two European cohorts, at 43% in England and 33% in Sweden, as reported by Clara Hellberg, PhD, MD, of Lund (Sweden) University. However, rates had increased over a 10-year study period from a respective 23% and 16%, with a sharp increase in use in the 2 years before knee replacement.

The analysis was based on 49,043 patients from the English national database Clinical Practice Research Datalink, and 5,955 patients from the Swedish Skåne Healthcare register who had undergone total knee replacement between 2015 and 2019 and were matched by age, sex and general practice to individuals not undergoing knee replacement.

The prevalence ratio for using opioids over a 10-year period increased from 1.6 to 2.7 in England, and from 1.6 to 2.6 in Sweden.

“While the overall prevalence of opioid use was higher in England, the majority of both cases and controls were using weak opioids,” Dr. Hellberg said.

“Codeine was classified as a weak opioid, whereas morphine was classified as a strong opioid,” she added.

In contrast, the proportion of people using strong opioids in Sweden was greater than in England, she said.

The high opioid use found in the study highlights “the need for better opioid stewardship, and the availability of acceptable, effective alternatives,” Dr. Hellberg and associates concluded in their abstract.

The study presented by Ms. Costa was funded by the Portuguese national funding agency for science, research and technology and by an independent research grant from Pfizer. Dr. Rhon acknowledged grant funding from the National Institutes of Health and the U.S. Department of Defense. Dr. Hellberg had no conflicts of interest to disclose.

Pages

Recommended Reading

Telemedicine models show some benefit in OA
Journal of Clinical Outcomes Management
Novel lupus therapies take center stage
Journal of Clinical Outcomes Management
FDA warning letters target OTC cannabidiol product claims for pain relief
Journal of Clinical Outcomes Management
COVID-19 vaccination in RMD patients: Safety data “reassuring”
Journal of Clinical Outcomes Management
Self-directed digital exercise plan improves knee OA
Journal of Clinical Outcomes Management
AAOS updates guidelines for nonoperative knee OA treatment
Journal of Clinical Outcomes Management
Platelet-rich plasma injections show no benefit in knee OA in placebo-controlled trial
Journal of Clinical Outcomes Management
Medical cannabis may cut opioid use for back pain, OA
Journal of Clinical Outcomes Management
Early meniscal surgery on par with active rehab in under 40s
Journal of Clinical Outcomes Management
Weight gain may exacerbate structural damage in knee OA
Journal of Clinical Outcomes Management